No abstract

No abstract

1 Weber J, Mandala M, Vecchia M et al. Adjuvant nivolumab versus ipilimumab in resected stage iii or iv melanoma. N Engl J Med 2017; 377: 1824-1835. 2 Wang DY, Salem J, Cohen JV et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and metaanalysis. JAMA Oncol 2018; 4: 1721-1728. 3 Schubert D, Bode C, Kenefeck R et al. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med 2014; 20: 1410-1416. 4 Larkin J, Chiarion-Sileni V, Gonzalez R et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2019; 381: 1535-1546. 5 Di Giacomo AM, Danielli R, Calabr o L et al. Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at university hospital Siena (Italy).

No abstract